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Abstract
Background—“Discovery” research about molecular markers for diagnosis, prognosis, or 
prediction of response to therapy has frequently produced results that were not reproducible in 
subsequent studies. What are the reasons, and can observational cohorts be cultivated to provide 
strong and reliable answers to those questions?
Methods—Selected examples are used to illustrate: 1) What features of research design provide 
strength and reliability in observational studies about markers of diagnosis, prognosis, and 
response to therapy? 2) How can those design features be cultivated in existing observational 
cohorts, for example within RCTs, other existing observational research studies, or practice 
settings like HMOs?
Results—Examples include a study of RNA expression profiles of tumor tissue to predict 
prognosis of breast cancer; a study of serum proteomics profiles to diagnose ovarian cancer; and a 
study of stool-based DNA assays to screen for colon cancer. Strengths and weaknesses of 
observational study design features are discussed, along with lessons about how features that help 
assure strength might be “cultivated” in the future.
Conclusions and Impact—By considering these examples and others, it may be possible to 
develop a process of “cultivating cohorts” - in on-going RCTs, observational cohort studies, and 
practice settings like HMOs - that have strong features of study design. Such an effort could 
produce sources of data and specimens to reliably answer questions about the use of molecular 
markers in diagnosis, prognosis, and response to therapy.
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The challenge of observational research
A challenge for observational epidemiology in the 21st century is to advance clinical and 
public health practice by “bridging an evidence gap” in addressing questions along the 
translational continuum of T0–T4 phases. (1) In the last 10–20 years the focus of much 
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translational research has been on basic scientific discoveries (T0) and early descriptive non-
interventional studies (T1), about markers of sensitivity and specificity (to assess molecular 
markers for diagnosis), and about predictive value (to assess molecular markers for 
prognosis or prediction). A major problem is that many “discoveries” have turned out to be 
not reproducible in subsequent studies. (2–5) One reason for this lack of reproducibility is 
inattentiveness to epidemiologically sound study design and conduct, particularly when a 
study is “observational” and may not readily have the safeguards against bias that a 
randomized controlled clinical trial (RCT) can have. At one extreme, “convenience 
samples” might be used for discovery or for validation, where little or no attention has been 
given to “design of the study” that collected the specimens that receive extensive 
biochemical, molecular, or mathematical analysis. At another extreme are prospective 
carefully designed and conducted observational studies that produce results that are 
reproducible and change practice or provide a reliable foundation for future work. (6) From 
these experiences it has become clear that investigators in this translational domain need to 
understand principles of observational epidemiology study design and conduct and details of 
what makes some observational studies strong and others weak. Said another way, 
investigators need to understand that all the activities that occur before blood or tissue 
collection must be considered to be part of a “research study” whose methods will be 
described in detail in a research report, so that readers can judge the strength and potential 
reproducibility of a study result. Those activities include selecting subjects for study; 
arranging methods to collect and store specimens; and arranging comparisons (for example 
between people with and without cancer), so that they avoid systematic differences or bias 
between groups that cause incorrect and misleading results. Serious problems can occur 
when these details of design and conduct are thought of only after the biochemical, 
molecular, and mathematical analysis is done. Rather, they need to be considered at the 
onset of any study, prior to any analyses. (6)
With this background, it is useful for investigators working in translational research
• including researchers in basic science and technology as well as in clinical research
• to consider lessons from recent experiences:
1. What makes observational study design strong or weak?
2. Can we cultivate and leverage existing cohorts and, if necessary, create new 
ones?
The concept of leverage is appealing because it may be economical to utilize already-
existing infrastructure (see recommendations in this issue (7) [This ref is in this issue of 
CEPB and you will need to update.]). Examples of leveraging provide lessons about how to, 
in the future, further “cultivate” this kind of effort. The goal of this commentary is to begin a 
larger discussion about how to cultivate strong observational research in a deliberate, 
economical, and productive manner.
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Examples of strong observational research about molecular markers of 
diagnosis and prognosis
One example of successful leveraging of an observational study for prognosis assessed 
whether an RNA expression profile could predict prognosis of women who had had surgical 
treatment of breast cancer and were considering adjuvant therapy. The question was whether 
risk of cancer recurrence could be predicted; if the rate of recurrence were low enough, a 
woman might decide to forego the expense and side effects of adjuvant therapy. The study 
of the OncoTypeDx test, that assessed RNA expression profiles of tumor tissue taken at the 
time of surgery, was conducted “retrospectively” within an already-existing cohort. (8). The 
study utilized banked formalin-fixed paraffin-embedded (FFPE) tissue specimens, along 
with data from the already-completed NSABP B-14 randomized controlled clinical trial 
(RCT). In that study, the placebo group, having received no adjuvant therapy, could be 
assessed to see in whom breast cancer recurred and whether RNA expression of multiple 
genes in tumor tissue at initial surgery could predict risk of recurrence. In order to measure 
RNA levels in FFPE specimens, study investigators had to develop new technical methods 
to measure RNA in tissue that had not been quick-frozen but rather had been routinely-
collected as FFPE specimens. Development of that translational technology in effect 
unlocked a new universe of “already-completed” studies, like RCTs, as a source of data and 
specimens for molecular and mathematical analysis that could be utilized to study markers 
of prognosis and prediction.
An example of a strong observational study that was leveraged to answer a question about 
diagnosis addressed whether a blood-based proteomics test could be used for screening to 
find asymptomatic early ovarian cancer. Prior to this study several strong claims had been 
made about new blood-based proteomics markers for ovarian cancer screening that were 
much better - nearly 100% sensitive and specific - than the CA125 serum marker. (9, 10) 
Those claims, however, had been strongly disputed based on methodologic concerns, (4, 11, 
12) but the question of “how sensitive and how specific” remained unanswered. To test the 
initial assays as well as others, a high-quality already-completed RCT was leveraged to 
provide blinded assessment of 5 independent panels of markers. Blood specimens were 
selected from the biospecimen repository that had been already been created as part of 
NCI’s PLCO (Prostate, Lung, Colon, Ovary) RCT. (13) In that RCT, serial bloods had been 
drawn among people who were being followed for development of cancer, including ovarian 
cancer, so that a blood specimen obtained shortly before ovarian cancer diagnosis could be 
identified and used to assess whether a blood test could detect asymptomatic cancer. Each 
proteomic panel was “tested” on exactly the same serum specimens. This study found that 
none of the new assays did better than CA125. Although the PLCO study was a RCT, only 
its “observational” features were used in this assessment; randomization to one or the other 
intervention group and assessment of ovarian cancer mortality was not relevant in this 
added-on study about whether markers could detect cancer.
A lesson from this study is how a new research question and study can be piggybacked on to 
an RCT or well-designed cohort study in which repeated collection of blood or other 
specimens is done, in order to assess a diagnostic test. Such cultivation in the future might 
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involve adding collection of serial bloods (utilizing appropriate volumes and collection and 
storage practices) to on-going research cohorts like the Framingham Study, the Nurses’ 
Health Study, Women’s Health Initiative, or within practice cohorts like in an HMO like 
Kaiser-Permanente.
For both examples above, major challenges in “cultivation” involved arranging access to 
data and specimens, assuring that “enough” specimen was available, and utilizing, and 
sometimes developing, novel methodologies to assess available material (i.e. measuring 
RNA in formalin-fixed paraffin-embedded tissue; or measuring protein in small quantities of 
serum or plasma) to investigate questions that had not been asked or planned for in the 
original study.
A third example is a study not “piggybacked” onto a RCT or other existing infrastructure but 
that was prospectively-planned for the specific purpose of assessing a stool DNA test to 
detect colon cancer. (14) The study involved conducting screening colonoscopy (to 
determine the presence or absence of colon cancer) preceded by collection of stool samples 
that would then be examined for fecal DNA containing cancer cell DNA. The true state 
remained blinded to study investigators. While this study had a single dedicated purpose 
with focus on stool as the source of diagnostic information and on one panel of markers, it is 
easy to imagine cultivation of this type of resource for larger uses. For example, more stool 
specimen might be collected for other investigators to use in later discovery or validation of 
other stool-based assays. Or adding blood samples collected prior to the true state exam 
might be done, for other investigators to look at blood-based CRC markers. In a parallel 
manner, entirely different sources of specimens might be cultivated for studying a blood-
based test for CRC, by piggybacking specimen collection onto an ongoing RCT in which 
colonoscopy screening is already being done. (15) Such kinds of efforts might leverage, 
through a small amount of additional funds or infrastructure, studies whose main expense 
(learning the true state by colonoscopy) was already in place. Or such an infrastructure 
might be appropriately added onto a large HMO or other medical practice.
These examples illustrate how one study may be leveraged to evaluate multiple markers and 
multiple different questions. (5) The examples illustrate the kinds of challenges that must be 
addressed in an effort to “cultivate”: Is “study” design and conduct (including the activities 
that happen before specimens are collected) strong-enough, overall, to produce reliable 
unbiased comparisons and results? Is “enough” specimen obtained, using the right collection 
and storage methods, for multiple users? These examples begin to provide lessons about 
how cohort studies, done for some other purpose, might be “added to” or cultivated in ways 
that let them be sources of specimens and data for “strongly designed and conducted” 
studies of diagnosis, prognosis, and prediction in observational translational research about 
T0 and T1 questions.
Next steps
It will be useful to consider additional examples and lessons about how cohorts may be 
cultivated. What makes a cohort strong or weak regarding challenges of bias and 
generalizability? What are potential sources of data and specimens and their strengths and 
Ransohoff Page 4













weaknesses, including RCTs, observational cohort research studies, and practice cohorts like 
in HMOs? (5) Will these resources be willing to openly share data and specimens for 
research questions that the original study did not set out to address? What features might 
need to be added, to “cultivate” existing infrastructure, to have the strong design and 
conduct that ultimately will be reported in a Methods section? Can such approaches lead to 
strong and reliable comparisons as would be arranged in a dedicated, prospectively designed 
and conducted formal study? The challenge is not just to ensure sharing of data or specimens 
that have already been collected. Indeed, such sharing is already being done or planned 
among major cohort resources like NCI’s Cohort Consortium or NCI’s Cancer Research 
Network. A more fundamental challenge is to make sure that the data and specimens 
collected in a cohort can be part of a “study” with features of “study design” that provide 
unbiased comparisons and generalizable results. (5, 6) In cultivating those features, for 
example, do new types of outcome data or exposure data (or specimens) need to be 
collected? If so, when and how? Does blinding need to be arranged to avoid serious biases; 
if so, then in what places in “design”? Identifying and addressing these kinds of challenges 
may help to grow new sources of material that can be used to strengthen T0 and T1 
translational research to advance clinical and public health practice.
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